US-based pharmaceutical giant Pfizer could still ink the industry’s largest takeover even after being rejected for such a deal by UK’s AstraZeneca, say reports.
AstraZeneca rejected Pfizer’s takeover offer last May, a deal that would have been a record purchase for the market at $118 billion. But Pfizer may now pursue …read more
Source: Global Competition Law Blogs